Robert P.Good, MD
Former Chief of Orthopaedics, Bryn Mawr Hospital & longtime Team Physician, Villanova Men’s Basketball
A device company built around one unsolved problem.
Caeruleum Biotechnologies, Inc. is a preclinical orthopaedic medical device company. The LunaFlex Meniscus is designed to restore physiologic load distribution across the tibiofemoral joint, to mitigate progression to post-traumatic osteoarthritis, and to give the joint a durable mechanical solution measured in decades rather than years.
Origin
The design came first. The company followed.
The first concepts and sketches for LunaFlex were developed in early October 2015. The earliest work began with a straightforward question: if damaged or missing meniscal tissue could not be repaired, could a synthetic structure be designed to restore the meniscus’s load-distributing role rather than simply remove more tissue?
That question became a long-running design program. The original concept evolved through repeated work on the implant’s geometry, fiber-reinforced structure, and intended implant fit and sizing. This research culminated in U.S. Patent No. 11,147,677, which was filed in January 2017 and granted in October 2021.
Over the following decade – as the paths of Caeruleum’s founders converged and led to the company’s formation in 2022 – the surgical technique, fixation structure, material selection, and market and regulatory positioning were refined. Caeruleum was built to carry that early invention forward as the LunaFlex platform and prepare the program for public launch.
Intellectual property
The protected structure at the center of LunaFlex.
The intellectual property supporting Caeruleum’s LunaFlex program is anchored by U.S. Patent No. 11,147,677, “Artificial meniscus,” which describes a fiber-reinforced composite meniscus encased in a bioresorbable scaffold.
A further provisional patent application was filed in April 2026, extending the estate to the fixation system, surgical instruments, and AI- and machine-learning–enabled preoperative sizing and planning software.
The issued patent is a public document, and anyone evaluating the program can read its claims in full:
Why now
Three decades defined the device.The last three years defined the timing.
The design problem is old. What has changed recently is the ground it lands on.
Regulatory clarity
A 2023 FDA advisory panel clarified what a meniscal implant in this class must demonstrate, providing a defined path for development and evaluation.
Materials maturity
The materials behind the design have established safety histories and are already in production, reducing novel-material and supply-chain uncertainty.
Payer pressure
Evidence questioning arthroscopic partial meniscectomy has increased payer interest in durable, joint-preserving alternatives that do not yet exist.
FDA Orthopaedic and Rehabilitation Devices Panel, 2023 · Sihvonen et al., FIDELITY, NEJM, 2013.
Clinical advisory board
Key Opinion Leaders
Our clinical advisors bring experience in orthopaedic surgery, sports medicine, quality and safety, and health economics to the development of the LunaFlex program.
Eric L.Hume, MD
Former Director of Orthopaedic Quality & Safety, Penn Medicine & Senior Fellow, Leonard Davis Institute
Matthew T.Kleiner, MD
Sports Medicine Surgeon at Cooper University Hospital & Team Physician for Rowan University Athletics
Mindy George-Weinstein, PhD
Former Chief Research & Science Officer & Board Trustee, Philadelphia College of Osteopathic Medicine
Continue exploring
Follow the program from problem to platform.
Go deeper into the LunaFlex design or meet the people advancing it.